Segment Reporting - Schedule of Segment Net Loss, Including Disaggregated Components of Operating Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Segment Reporting Information [Line Items] | ||||||
| Collaboration revenue | $ 937 | $ 510 | $ 1,503 | $ 1,150 | ||
| Research and development: | ||||||
| Manufacturing costs | 10,000 | 1,416 | 12,129 | 1,641 | ||
| Personnel expenses | 4,509 | 2,404 | 8,214 | 4,839 | ||
| Professional fees and other | 1,079 | 1,242 | 2,571 | 2,542 | ||
| Total research and development expenses | 37,865 | 14,069 | 63,662 | 25,760 | ||
| General and administrative: | ||||||
| Personnel expenses | 3,773 | 2,313 | 8,005 | 4,689 | ||
| Professional fees | 2,397 | 1,334 | 3,893 | 2,461 | ||
| Other | 1,249 | 334 | 2,303 | 793 | ||
| Total general and administrative expenses | 7,419 | 3,981 | 14,201 | 7,943 | ||
| Total operating expenses | 45,284 | 18,050 | 77,863 | 33,703 | ||
| Loss from operations | (44,347) | (17,540) | (76,360) | (32,553) | ||
| Other income (expense): | ||||||
| Change in fair value of preferred stock tranche right liabilities | 0 | 0 | 0 | 2,859 | ||
| Interest income | 4,431 | 2,877 | 9,174 | 4,143 | ||
| Other expense, net | (50) | (15) | (50) | (21) | ||
| Total other income, net | 4,381 | 2,862 | 9,124 | 6,981 | ||
| Net loss | (39,966) | $ (27,270) | (14,678) | $ (10,894) | (67,236) | (25,572) |
| Asthma Indication | ||||||
| Research and development: | ||||||
| Verekitug program | 13,236 | 6,935 | 23,257 | 13,102 | ||
| CRSwNP Indication | ||||||
| Research and development: | ||||||
| Verekitug program | 2,238 | $ 2,072 | 5,001 | $ 3,636 | ||
| COPD Indication | ||||||
| Research and development: | ||||||
| Verekitug program | $ 6,803 | $ 12,490 | ||||
| X | ||||||||||
- Definition Change in fair value of preferred stock tranche right liabilities. No definition available.
|
| X | ||||||||||
- Definition General and administrative personnel expense. No definition available.
|
| X | ||||||||||
- Definition General and administrative professional fees expenses. No definition available.
|
| X | ||||||||||
- Definition Other nono.perating income expenses No definition available.
|
| X | ||||||||||
- Definition Professional fees and other research and development expense. No definition available.
|
| X | ||||||||||
- Definition Research and development personnel expense. No definition available.
|
| X | ||||||||||
- Definition Research and development program expense. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred in the production of goods for sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|